Evidence map›Paper›PMID 28947749›Full record

ArticleScientific reports2017

Exploitation of a newly-identified entry pathway into the malaria parasite-infected erythrocyte to inhibit parasite egress.

Svetlana Glushakova, Brad L Busse, Matthias Garten, Josh R Beck, Rick M Fairhurst, Daniel E Goldberg, Joshua Zimmerberg

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Unveiling the Sugary Secrets ofFrontiers in microbiology · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. eLife · 2019
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Svetlana GlushakovaSection on Integrative Biophysics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
Brad L BusseSection on Integrative Biophysics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
Matthias GartenSection on Integrative Biophysics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID 0000-0002-8660-1039
Josh R BeckDivision of Infectious Diseases, Department of Medicine, Washington University, St. Louis, MO, 63110, USA.
Rick M FairhurstLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases; National Institutes of Health, Bethesda, MD, 20892, USA.
Daniel E GoldbergDivision of Infectious Diseases, Department of Medicine, Washington University, St. Louis, MO, 63110, USA.
Joshua ZimmerbergSection on Integrative Biophysics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA. joshz@helix.nih.gov.ORCID 0000-0002-1707-3789
National Institutes of Health · USWashington University in St. Louis · US

Funding

Membrane Remodeling in Viral Infection, Parasite Replication, and Traumatic Brain InjuryZIAHD001409 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI ZIMMERBERG, JOSHUA · 2009 to 2025
$29.9M
Infectious Diseases/Basic Microbial Pathogenic MechanismsT32AI007172 · NIAID · WASHINGTON UNIVERSITY · PI Daniel E. Goldberg, JENNIFER A PHILIPS · 1985 to 2026
$13.0M
IDENTIFICATION OF THE ANTIMALARIAL TARGET OF PEPSTATIN ESTERSR01AI112508 · NIAID · WASHINGTON UNIVERSITY · PI GOLDBERG, DANIEL E. · 2014 to 2018
$1.9M
Erythrocyte Subversion by Malaria Parasite Exported EffectorsR00HL133453 · NHLBI · IOWA STATE UNIVERSITY · PI BECK, JOSH RYAN · 2017 to 2019
$747k
Erythrocyte Subversion by Malaria Parasite Exported EffectorsK99HL133453 · NHLBI · WASHINGTON UNIVERSITY · PI BECK, JOSH RYAN · 2016 to 2017
$166k
NHLBI NIH HHS K99 HL133453NHLBI NIH HHS R00 HL133453NIAID NIH HHS R01 AI112508NIAID NIH HHS T32 AI007172
6 · The paper itself

Abstract

While many parasites develop within host cells to avoid antibody responses and to utilize host cytoplasmic resources, elaborate egress processes have evolved to minimize the time between escaping and invading the next cell. In human erythrocytes, malaria parasites perforate their enclosing erythrocyte membrane shortly before egress. Here, we show that these pores clearly function as an entry pathway into infected erythrocytes for compounds that inhibit parasite egress. The natural glycosaminoglycan heparin surprisingly inhibited malaria parasite egress, trapping merozoites within infected erythrocytes. Labeled heparin neither bound to nor translocated through the intact erythrocyte membrane during parasite development, but fluxed into erythrocytes at the last minute of the parasite lifecycle. This short encounter was sufficient to significantly inhibit parasite egress and dispersion. Heparin blocks egress by interacting with both the surface of intra-erythrocytic merozoites and the inner aspect of erythrocyte membranes, preventing the rupture of infected erythrocytes but not parasitophorous vacuoles, and independently interfering with merozoite disaggregation. Since this action of heparin recapitulates that of neutralizing antibodies, membrane perforation presents a brief opportunity for a new strategy to inhibit parasite egress and replication.

Indexed as

ErythrocytesExocytosisHeparinHumansMerozoitesPlasmodiumHeparin

Identifiers

PMID28947749
PMCPMC5612957
OpenAlexW2754816770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.